Leukemia
Leukemia
Advertisement
Dustin SamplesLeukemia | January 17, 2023
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Read More
Leah LawrenceTreatment | January 10, 2023
A recently approved TIW schedule provides new option for patients with ALL or LBL receiving asparaginase.
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Emily MenendezLeukemia | December 12, 2022
TKI resistance can cause challenges for patients with CML. New research seeks to identify biomarkers of early resistance.
Leah LawrenceLeukemia | December 7, 2022
A single-center study shows promising results using ponatinib and blinatumomab, including overall response rate.
Leah LawrenceBest Practices | November 28, 2022
These results indicate that nurses can lead exercise activity for ambulatory, alert, and oriented adult leukemia patients.
Patrick DalyLeukemia | November 29, 2021
Researchers, led by Katharine McLaughlin, examined the relationship between changes in vital signs and admission to an ...
Patrick DalyLeukemia | November 29, 2021
Researchers performed a meta-analysis to evaluate two hypomethylating agents (HMAs), decitabine and azacitidine, in the ...
Patrick DalyLeukemia | November 29, 2021
Findings from a randomized trial, published in The Lancet Oncology, showed that combining enasidenib with azacitidine was ...
Patrick DalyLeukemia | November 29, 2021
Researchers developed a method to measure standardized intracellular reactive oxygen species (siROS) levels in the CD34+ bone ...
Patrick DalyLeukemia | November 10, 2021
In a systematic review and meta-analysis, researchers assessed the efficacy and safety of gemtuzumab ozogamicin (GO) in ...
Ariel JonesLeukemia | October 25, 2021
In a case report published in the Journal of Oncology Pharmacy Practice, researchers described an incident of aplastic anemia ...
Ariel JonesLeukemia | October 25, 2021
A study in Blood has found that nearly 14% of adult patients with acute myeloid leukemia (AML) have pathogenic or likely ...
Ariel JonesLeukemia | October 12, 2021
Researchers analyzed baseline patient characteristics and first-line treatments on survival and CML–related mortality.
Ariel JonesLeukemia | September 28, 2021
In a phase III study published in Blood, asciminib was associated with higher rates of major molecular response (MMR) than ...
Ariel JonesLeukemia | September 28, 2021
Older patients with previously untreated acute myeloid leukemia (AML) who received oblimersen plus standard conventional ...
Ariel JonesLeukemia | September 13, 2021
According to findings published in Lancet Haematology, the addition of the BCL2 inhibitor venetoclax to intensive ...
Ariel JonesLeukemia | September 13, 2021
The prospective, randomized SPIRIT trial, conducted in France, compared long-term outcomes with imatinib and imatinib ...
Ariel JonesLeukemia | August 31, 2021
In a phase II, open-label study of pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML), ...
Keightley AmenLeukemia | July 20, 2021
In an integrated human and murine clinical study of chronic myelomonocytic leukemia (CMML), treatment with ruxolitinib led to ...
Advertisement
Advertisement
Advertisement